<DOC>
	<DOCNO>NCT01527357</DOCNO>
	<brief_summary>The primary objective study demonstrate superiority Fibrocaps plus gelatin sponge , compare gelatin sponge alone , achieve hemostasis subject mild moderate surgical bleeding spine , liver , vascular soft tissue surgery . This Phase 3 , international , multi-center , randomize , single-blind , controlled trial conduct clinical trial site European Union United States .</brief_summary>
	<brief_title>Phase 3 Study Fibrocapsâ„¢ Surgical Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<mesh_term>Gelatin Sponge , Absorbable</mesh_term>
	<mesh_term>Fibrin Foam</mesh_term>
	<criteria>1 . Subject sign institutional review board/independent ethic committee ( IRB/IEC ) approve informed consent document 2 . Subject undergo one 4 surgical procedure describe 3 . Subject age &gt; 18 year time consent 4 . If female childbearing potential , subject negative pregnancy test screen breastfeed 5 . If subject sexually active male sexually active female childbearing potential , subject agrees use medically accept form contraception time consent completion followup study visit 6 . Subject receive blood transfusion screen study treatment 7 . Presence mild moderate surgical bleeding 8 . Absence intraoperative complication 9 . No intraoperative use topical hemostat contain thrombin prior study treatment 10 . Approximate bleed site surface area less equal 100 cm2 1 . Subject known antibody hypersensitivity thrombin coagulation factor 2 . Subject history heparininduced thrombocytopenia ( vascular subject heparin use require ) 3 . Subject know allergy porcine gelatin 4 . Subject unwilling receive blood product 5 . Has clinicallysignificant coagulation disorder may interfere assessment efficacy pose safety risk subject accord Investigator , baseline abnormality INR &gt; 2.5 aPTT &gt; 100 second screen explain current drug treatment ( e.g. , warfarin , heparin ) 6 . Aspartate Aminotransferase ( ASAT/AST ) Alanine aminotransferase ( ALAT/ALT ) &gt; 3 x upper limit normal range screening , except subject undergo liver resection surgery diagnosis liver metastases upper limit analytes due nature disease 7 . Platelets &lt; 100 x109 PLT/L screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>fibrin sealant</keyword>
	<keyword>thrombin</keyword>
	<keyword>fibrinogen</keyword>
	<keyword>hemostasis</keyword>
</DOC>